Coya Therapeutics Publishes New Research Linking Inflammation to Parkinson’s Progression, Supporting Broader Treatment Potential

Published study supports dual-immunomodulatory approach as Coya advances COYA 302 across neuroinflammatory diseases
Coya Therapeutics (Nasdaq: COYA) has announced the publication of new research in Frontiers in Immunology that underscores the role of peripheral immune dysfunction in the progression of Parkinson’s disease (PD). The study, co-authored by Dr. Aaron Thome and Coya Scientific Advisory Board Chair Dr. Stanley H. Appel, adds to growing evidence that inflammation and oxidative stress are key contributors to PD.
The cross-sectional analysis of monocytes from PD patients and matched controls revealed clear inflammatory and oxidative signatures that increased with disease severity. These findings support the scientific rationale for COYA 302, the company’s investigational dual-mechanism immunomodulatory therapy currently in development.
Dr. Appel commented, “The data offer strong insights into how peripheral inflammation is a key driver of the pathophysiology of PD.” Chief Medical Officer Dr. Fred Grossman added that the study “confirm our findings in other serious neurodegenerative diseases driven by sustained inflammation and strengthen our multitargeted immunomodulatory approach as a strategy for treating severe conditions with high unmet needs.”
Coya’s investigational product COYA 302 combines low-dose interleukin-2 with CTLA-4 Ig to enhance regulatory T cell function while suppressing inflammation from activated monocytes and macrophages. While currently in development for ALS, the therapeutic platform may have broader applicability across neuroinflammatory diseases including Parkinson’s.
This research follows prior sponsored studies linking similar inflammatory mechanisms to ALS, FTD, and Alzheimer’s disease, further validating Coya’s targeted approach to treating neurodegeneration at the immune system level.
Watch the latest video with Coya CEO, Arun Swaminathan, Ph.D.: https://youtu.be/Z0f83vdJwqI?feature=shared
As Coya continues to build scientific validation around its dual-immunomodulatory platform, several meaningful milestones lie ahead that could further reinforce the potential of its therapeutic strategy:
- 1Q 2025: Publication of additional systemic immune and cerebrospinal fluid biomarker data from Phase 2 low-dose IL-2 trial in Alzheimer’s disease (milestone met)
- 1Q–2Q 2025: COYA 303 combination mechanistic data publication and additional IP filings (milestone met)
- 2Q 2025: Submission to FDA of data package to support initiation of COYA 302 Phase 2 trial in ALS (submitted on 30 June , 2025)
- If accepted by FDA and first patient is dosed, Coya will be eligible for $8.4 million in non-dilutive milestone payments from strategic partner Dr. Reddy’s Laboratories
- 2H 2025: Topline clinical data from investigator-initiated study of LD IL-2 plus CTLA-4 Ig in FTD patients
- 2H 2025: IND filing for COYA 302 Phase 2 trial in FTD
With a focused pipeline, strong scientific leadership, and strategic partnerships, Coya continues to advance its goal of improving outcomes for patients living with serious neuroinflammatory diseases.
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

















